Diagnosis and management of Chagas disease and cardiomyopathy

Nature Reviews Cardiology

Volumn 9, Issue 10, 2012, Pages 576-589

  Ribeiro, Antonio L ^a   Nunes, Maria P ^a   Teixeira, Mauro M ^a   Rocha, Manoel O C ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CYSTEINE PROTEINASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRONEDARONE; E 1224; K 777; K777; NIFURTIMOX; POSACONAZOLE; PRODRUG; RAVUCONAZOLE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CHAGAS DISEASE; CLINICAL FEATURE; DEFIBRILLATOR; DERMATITIS; DIAGNOSTIC IMAGING; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ENDEMIC DISEASE; EUROPE; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; INFLAMMATION; INSOMNIA; IRRITABILITY; MIGRATION; MYOCARDIAL DISEASE; NORTH AMERICA; PARASITISM; PATHOGENESIS; PERSISTENT INFECTION; POLYNEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SOUTH AND CENTRAL AMERICA; THROMBOEMBOLISM; TRYPANOSOMA CRUZI; URTICARIA;

ADRENERGIC BETA-ANTAGONISTS; BIOLOGICAL MARKERS; CHAGAS CARDIOMYOPATHY; HUMANS; LATIN AMERICA; PROGNOSIS; RISK FACTORS; TRYPANOCIDAL AGENTS; UNITED STATES;

EID: 84866730697     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.109     Document Type: Review

References (180)

1. WHO. Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases [online], http://whqlibdoc.who.int/publications/2010/9789241564090-eng.pdf (2010).
2. WHO. Chagas disease: control and elimination (A63/17) [online], http://apps.who.int/gb/ebwha/pdf-files/WHA63/A63-17-en.pdf (2010).
3. Schmunis, G. A. & Yadon, Z. E. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop. 115, 14-21 (2010).
4. Rocha, M. O., Teixeira, M. M. & Ribeiro, A. L. An update on the management of Chagas cardiomyopathy. Expert Rev. Anti. Infect. Ther. 5, 727-743 (2007).
5. Biolo, A., Ribeiro, A. L. & Clausell, N. Chagas cardiomyopathy-where do we stand after a hundred years? Prog. Cardiovasc. Dis. 52, 300-316 (2010).
6. Stimpert, K. K. & Montgomery, S. P. Physician awareness of Chagas disease, USA. Emerg. Infect. Dis. 16, 871-872 (2010).
7. Coura, J. R. & Viñas, P. A. Chagas disease: a new worldwide challenge. Nature 465, S6-S7 (2010).
8. Garraud, O., Andreu, G., Elghouzzi, M. H., Laperche, S. & Lefrère, J. J. Measures to prevent transfusion-associated protozoal infections in non-endemic countries. Travel Med. Infect. Dis. 5, 110-112 (2007).
9. Prata, A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis. 1, 92-100 (2001).
10. Shikanai-Yasuda, M. A. & Carvalho, N. B. Oral transmission of Chagas disease. Clin. Infect. Dis. 54, 845-852 (2012).
11. Herwaldt, B. L. Laboratory-acquired parasitic infections from accidental exposures. Clin. Microbiol. Rev. 14, 659-688 (2001).
12. Schofield, C. J. & Dias, J. C. The Southern Cone Initiative against Chagas disease. Adv. Parasitol. 42, 1-27 (1999).
13. Moncayo, A. & Silveira, A. C. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem. Inst. Oswaldo Cruz 104 (Suppl. 1), 17-30 (2009).
14. Schofield, C. J., Jannin, J. & Salvatella, R. The future of Chagas disease control. Trends Parasitol. 22, 583-588 (2006).
15. Petherick, A. Country by country. Nature 465, S10-S11 (2010).
16. Gürtler, R. E., Kitron, U., Cecere, M. C., Segura, E. L. & Cohen, J. E. Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina. Proc. Natl Acad. Sci. USA 104, 16194-16199 (2007).
17. Coura, J. R. & Junqueira, A. C. Risks of endemicity, morbidity and perspectives regarding the control of Chagas disease in the Amazon Region. Mem. Inst. Oswaldo Cruz 107, 145-154 (2012).
18. Aguilar, H. M., Abad-Franch, F., Dias, J. C., Junqueira, A. C. & Coura, J. R. Chagas disease in the Amazon Region. Mem. Inst. Oswaldo Cruz 102 (Suppl. 1), 47-56 (2007).
19. Martins-Melo, F. R., Alencar, C. H., Ramos, A. N. Jr & Heukelbach, J. Epidemiology of mortality related to Chagas' disease in Brazil, 1999-2007. PLoS. Negl. Trop. Dis. 6, e1508 (2012).
20. Lima-Costa, M. F., Matos, D. L. & Ribeiro, A. L. Chagas disease predicts 10-year stroke mortality in community-dwelling elderly: the Bambuí cohort study of aging. Stroke 41, 2477-2482 (2010).
21. Lima-Costa, M. F., Peixoto, S. V. & Ribeiro, A. L. Chagas disease and mortality in old age as an emerging issue: 10 year follow-up of the Bambuí population-based cohort study (Brazil). Int. J. Cardiol. 145, 362-363 (2010).
22. Schmunis, G. A. Epidemiology of Chagas disease in non endemic countries: the role of international migration. Mem. Inst. Oswaldo Cruz 102 (Suppl. 1), 75-85 (2007).
23. Bern, C. & Montgomery, S. P. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis. 49, e52-e54 (2009).
24. Bern, C., Kjos, S., Yabsley, M. J. & Montgomery, S. P. Trypanosoma cruzi and Chagas' disease in the United States. Clin. Microbiol. Rev. 24, 655-681 (2011).
25. Basile, L. et al. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill. 16, 1-10 (2011).
26. WHO. Control and prevention of Chagas disease in Europe. Report of a WHO informal consultation (jointly organized by WHO headquarters and the WHO regional office for Europe) [online], http://www.fac.org.ar/1/comites/chagas/ Chagas-WHO-Technical%20Report-16-06-10.pdf (2009).
27. Cantey, P. T. et al. The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion http://dx.doi.org/10.1111/ j.1537-2995.2012.03581.x.
28. Talvani, A. & Teixeira, M. M. Inflammation and Chagas disease some mechanisms and relevance. Adv. Parasitol. 76, 171-194 (2011).
29. Gutierrez, F. R., Guedes, P. M., Gazzinelli, R. T. & Silva, J. S. The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol. 31, 673-685 (2009).
30. Nagajyothi, F. et al. Mechanisms of Trypanosoma cruzi persistence in Chagas disease. Cell. Microbiol. 14, 634-643 (2012).
31. Dutra, W. O., Rocha, M. O. & Teixeira, M. M. The clinical immunology of human Chagas disease. Trends Parasitol. 21, 581-587 (2005).
32. Köberle, F. Chagas' disease and Chagas' syndromes: the pathology of American trypanosomiasis. Adv. Parasitol. 6, 63-116 (1968).
33. Prado, C. M. et al. The vasculature in Chagas disease. Adv. Parasitol. 76, 83-99 (2011).
34. Cunha-Neto, E., Teixeira, P. C., Nogueira, L. G. & Kalil, J. Autoimmunity. Adv. Parasitol. 76, 129-152 (2011).
35. Machado, F. S. et al. Pathogenesis of Chagas disease: time to move on. Front. Biosci. (Elite Ed.) 4, 1743-1758 (2012).
36. Marin-Neto, J. A., Cunha-Neto, E., Maciel, B. C. & Simões, M. V. Pathogenesis of chronic Chagas heart disease. Circulation 115, 1109-1123 (2007).
37. Bern, C. Chagas disease in the immunosuppressed host. Curr. Opin. Infect. Dis. http://dx.doi.org/10.1097/QCO.0b013e328354f179.
38. Bern, C., Martin, D. L. & Gilman, R. H. Acute and congenital Chagas disease. Adv. Parasitol. 75, 19-47 (2011).
39. Machado, F. S., Tanowitz, H. B. & Teixeira, M. M. New drugs for neglected infectious diseases: Chagas' disease. Br. J. Pharmacol. 160, 258-259 (2010).
40. Coura, J. R. & Borges-Pereira, J. Chagas disease: 100 years after its discovery. A systemic review. Acta Trop. 115, 5-13 (2010).
41. Romaña, C. Acerca de un síntoma inicial de valor para el diagnóstico de la forma aguda de la enfermedad de Chagas [Spanish]. La conjuntivitis schizotripanosómica unilateral (hipótesis sobre la puerta de entrada conjuntival de la enfermedad). Mision de Estudios de Patologia Regional Argentina (MEPRA) 35, 16-25 (2012).
42. Ribeiro, A. L. & Rocha, M. O. Indeterminate form of Chagas disease: considerations about diagnosis and prognosis [Portuguese]. Rev. Soc. Bras. Med. Trop. 31, 301-314 (1998).
43. Dias, J. C. The indeterminate form of human chronic Chagas' disease: a clinical epidemiological review. Rev. Soc. Bras. Med. Trop. 22, 147-156 (1989).
44. Marin-Neto, J. A., Almeida Filho, O. C., Pazin-Filho, A. & Maciel, B. C. Indeterminate form of Chagas' disease. Proposal of new diagnostic criteria and perspectives for early treatment of cardiomyopathy [Portuguese]. Arq. Bras. Cardiol. 79, 623-627 (2002).
45. Viotti, R. J. et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 90, 655-660 (2004).
46. Rochitte, C. E. et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J. Am. Coll. Cardiol. 46, 1553-1558 (2005).
47. Barros, M. V., Rocha, M. O., Ribeiro, A. L. & Machado, F. S. Tissue Doppler imaging in the evaluation of the regional diastolic function in Chagas' disease. Eur. J. Echocardiogr. 2, 94-99 (2001).
48. Garcia-Alvarez, A. et al. Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage. PLoS Negl. Trop. Dis. 4, e826 (2010).
49. Molina, R. B. et al. Dysautonomia and ventricular dysfunction in the indeterminate form of Chagas disease. Int. J. Cardiol. 113, 188-193 (2006).
50. Ribeiro, A. L., Campos, M. S., Baptista, L. M. & de Sousa, M. R. The Valsalva maneuver in Chagas disease patients without cardiopathy. Clin. Auton. Res. 20, 79-83 (2010).
51. Oliveira, E., Ribeiro, A. L., Assis Silva, F., Torres, R. M. & Rocha, M. O. The Valsalva maneuver in Chagas disease patients without cardiopathy. Int. J. Cardiol. 82, 49-54 (2002).
52. Ianni, B. M., Arteaga, E., Frimm, C. C., Pereira Barretto, A. C. & Mady, C. Chagas' heart disease: evolutive evaluation of electrocardiographic and echocardiographic parameters in patients with the indeterminate form. Arq. Bras. Cardiol. 77, 59-62 (2001).
53. Storino, R., Milei, J., Manzullo, E. C. & Darraidou, M. Evolucion natural y estudios longitudinales, in Enfermedad de Chagas (eds Storino, R. & Milei, J.) 593-604 (Inter-médica, Buenos Aires, 1994).
54. Coura, J. R. Chagas disease: what is known and what is needed-A background article. Mem. Inst. Oswaldo Cruz 102 (Suppl. 1), 113-122 (2007).
55. Pinto Dias, J. C. Natural history of Chagas disease [Portuguese]. Arq. Bras. Cardiol. 65, 359-366 (1995).
56. Marin Neto, J. A., Simões, M. V. & Sarabanda, A. V. Chagas' heart disease. Arq. Bras. Cardiol. 72, 247-280 (1999).
57. Rocha, M. O., Ribeiro, A. L. & Teixeira, M. M. Clinical management of chronic Chagas cardiomyopathy. Front. Biosci. 8, e44-e54 (2003).
58. Viotti, R. et al. Clinical predictors of chronic chagasic myocarditis progression [Spanish]. Rev. Esp. Cardiol. 58, 1037-1044 (2005).
59. Carrasco, H. A. et al. Ventricular arrhythmias and left ventricular myocardial function in chronic chagasic patients. Int. J. Cardiol. 28, 35-41 (1990).
60. [No authors listed.] Brazilian consensus on Chagas disease. Rev. Soc. Bras. Med. Trop. 38 (Suppl. 3), 7-29 (2005).
61. Brasil, P. E., de Castro, L., Hasslocher-Moreno, A. M., Sangenis, L. H. & Braga, J. U. ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect. Dis. 10, 337 (2010).
62. Brasil, P. E., De Castro, L., Hasslocher-Moreno, A. M., Sangenis, L. H. & Braga, J. U. ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect. Dis. 10, 337 (2010).
63. Diez, M. et al. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am. J. Transplant. 7, 1633-1640 (2007).
64. Schijman, A. G. et al. Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. J. Antimicrob. Chemother. 52, 441-449 (2003).
65. Maguire, J. H. et al. Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation 75, 1140-1145 (1987).
66. Nascimento, B. R. et al. The prognostic significance of electrocardiographic changes in Chagas disease. J. Electrocardiol. 45, 43-48 (2012).
67. Porto, C. C. O eletrocardiograma no prognóstico e evolução da Doença de Chagas [Portuguese]. Arq. Bras. Cardiol. 17, 313-346 (1964).
68. Sternick, E. B. et al. Sudden cardiac death in patients with chagas heart disease and preserved left ventricular function. J. Cardiovasc. Electrophysiol. 17, 113-116 (2006).
69. de Paola, A. A., Gomes, J. A., Terzian, A. B., Miyamoto, M. H. & Martinez Fo, E. E. Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br. Heart J. 74, 293-295 (1995).
70. Rassi, A. Jr et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N. Engl. J. Med. 355, 799-808 (2006).
71. Rocha, A. L. et al. Chronotropic-metabolic index in Chagas' disease [Portuguese]. Rev. Soc. Bras. Med. Trop. 38, 373-376 (2005).
72. Rocha, A. L. et al. Chronotropic incompetence and abnormal autonomic modulation in ambulatory Chagas disease patients. Ann. Noninvasive Electrocardiol. 11, 3-11 (2006).
73. Grupi, C. J. et al. Holter monitoring in Chagas' heart disease. Sao Paulo Med. J. 113, 835-840 (1995).
74. Rassi, A. Jr, Rassi, A. & Rassi, S. G. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 115, 1101-1108 (2007).
75. Ribeiro, A. L. et al. Prognostic value of signal-averaged electrocardiogram in Chagas disease. J. Cardiovasc. Electrophysiol. 19, 502-509 (2008).
76. Martinelli Filho, M. et al. Clinical and electrophysiologic features of syncope in chronic chagasic heart disease. J. Cardiovasc. Electrophysiol. 5, 563-570 (1994).
77. Rincon, L. G. et al. Clinical profile of Chagas and non-Chagas' disease patients with cardiac pacemaker [Portuguese]. Rev. Soc. Bras. Med. Trop. 39, 245-249 (2006).
78. Leite, L. R. et al. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. J. Cardiovasc. Electrophysiol. 14, 567-573 (2003).
79. Perez, A. A. et al. Value of the radiological study of the thorax for diagnosing left ventricular dysfunction in Chagas' disease. Arq. Bras. Cardiol. 80, 208-213 (2003).
80. Barral, M. M. et al. Echocardiographic parameters associated with pulmonary congestion in Chagas cardiomyopathy. Rev. Soc. Bras. Med. Trop. 43, 244-248 (2010).
81. Acquatella, H. Echocardiography in Chagas heart disease. Circulation 115, 1124-1131 (2007).
82. Barros, M. L., Ribeiro, A., Nunes, M. C. & Rocha, M. O. Association between left ventricular wall motion abnormalities and ventricular arrhythmia in the indeterminate form of Chagas disease [Portuguese]. Rev. Soc. Bras. Med. Trop. 44, 213-216 (2011).
83. Pazin-Filho, A. et al. Minor segmental wall motion abnormalities detected in patients with Chagas' disease have adverse prognostic implications. Braz. J. Med. Biol. Res. 39, 483-487 (2006).
84. Acquatella, H., Pérez, J. E., Condado, J. A. & Sánchez, I. Limited myocardial contractile reserve and chronotropic incompetence in patients with chronic Chagas' disease: assessment by dobutamine stress echocardiography. J. Am. Coll. Cardiol. 33, 522-529 (1999).
85. Nunes, M. C., Barbosa, M. M. & Rocha, M. O. Peculiar aspects of cardiogenic embolism in patients with Chagas' cardiomyopathy: a transthoracic and transesophageal echocardiographic study. J. Am. Soc. Echocardiogr. 18, 761-767 (2005).
86. Carod-Artal, F. J. & Gascon, J. Chagas disease and stroke. Lancet Neurol. 9, 533-542 (2010).
87. Carod-Artal, F. J., Vargas, A. P. & Falcao, T. Stroke in asymptomatic Trypanosoma cruzi-infected patients. Cerebrovasc. Dis. 31, 24-28 (2011).
88. Nunes, M. C., Barbosa, M. M., Ribeiro, A. L., Barbosa, F. B. & Rocha, M. O. Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: a prospective follow-up study. J. Neurol. Sci. 278, 96-101 (2009).
89. Benchimol Barbosa, P. R. Noninvasive prognostic markers for cardiac death and ventricular arrhythmia in long-term follow-up of subjects with chronic Chagas' disease. Braz. J. Med. Biol. Res. 40, 167-178 (2007).
90. Nunes, M. C., Barbosa, M. M., Ribeiro, A. L., Colosimo, E. A. & Rocha, M. O. Left atrial volume provides independent prognostic value in patients with chagas cardiomyopathy. J. Am. Soc. Echocardiogr. 22, 82-88 (2009).
91. Rocha, M. O., Nunes, M. C. & Ribeiro, A. L. Morbidity and prognostic factors in chronic chagasic cardiopathy. Mem. Inst. Oswaldo Cruz 104 (Suppl. 1), 159-166 (2009).
92. Barros, M. V., Machado, F. S., Ribeiro, A. L. & Rocha, M. O. Diastolic function in Chagas' disease: an echo and tissue Doppler imaging study. Eur. J. Echocardiogr. 5, 182-188 (2004).
93. Barbosa, M. M., Nunes, M. C., Ribeiro, A. L., Barral, M. M. & Rocha, M. O. N-terminal proBNP levels in patients with Chagas disease: a marker of systolic and diastolic dysfunction of the left ventricle. Eur. J. Echocardiogr. 8, 204-212 (2007).
94. Oliveira, B. M. et al. Correlation between BNP levels and Doppler echocardiographic parameters of left ventricle filling pressure in patients with Chagasic cardiomyopathy. Echocardiography 26, 521-527 (2009).
95. Lima, M. M. et al. Left ventricular diastolic function and exercise capacity in patients with Chagas cardiomyopathy. Echocardiography 27, 519-524 (2010).
96. Nunes, M. P. et al. Different prognostic impact of the tissue Doppler-derived E/e' ratio on mortality in Chagas cardiomyopathy patients with heart failure. J. Heart Lung Transplant. 31, 634-641 (2012).
97. Marin-Neto, J. A. et al. Radionuclide angiographic evidence for early predominant right ventricular involvement in patients with Chagas' disease. Can. J. Cardiol. 4, 231-236 (1988).
98. Barros, M. V., Machado, F. S., Ribeiro, A. L. & Rocha, M. O. Detection of early right ventricular dysfunction in Chagas' disease using Doppler tissue imaging. J. Am. Soc. Echocardiogr. 15, 1197-1201 (2002).
99. Nunes, M. C., Barbosa, M. M., Brum, V. A. & Rocha, M. O. Morphofunctional characteristics of the right ventricle in Chagas' dilated cardiomyopathy. Int. J. Cardiol. 94, 79-85 (2004).
100. Nunes, M. C. et al. Functional capacity and right ventricular function in patients with Chagas heart disease. Eur. J. Echocardiogr. 11, 590-595 (2010).
101. Nunes, M. D. et al. Right ventricular dysfunction is an independent predictor of survival in patients with dilated chronic Chagas' cardiomyopathy. Int. J Cardiol. 127, 353-359 (2008).
102. Marin-Neto, J. A. et al. Myocardial perfusion abnormalities in chronic Chagas' disease as detected by thallium-201 scintigraphy. Am. J. Cardiol. 69, 780-784 (1992).
103. Simões, M. V. et al. Relation of regional sympathetic denervation and myocardial perfusion disturbance to wall motion impairment in Chagas' cardiomyopathy. Am. J. Cardiol. 86, 975-981 (2000).
104. Rochitte, C. E. et al. Cardiac magnetic resonance in Chagas' disease. Artif. Organs 31, 259-267 (2007).
105. Leme, A. M. et al. Evaluation of the metabolism of high energy phosphates in patients with Chagas' disease. Arq. Bras. Cardiol. 95, 264-270 (2010).
106. Ribeiro, A. L. et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet 360, 461-462 (2002).
107. Talvani, A. et al. Brain natriuretic peptide measurement in Chagas heart disease: marker of ventricular dysfunction and arrhythmia. Int. J. Cardiol. 100, 503-504 (2005).
108. Ribeiro, A. L. et al. Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. Int. J. Cardiol. 109, 34-40 (2006).
109. Lima-Costa, M. F., Cesar, C. C., Peixoto, S. V. & Ribeiro, A. L. Plasma B-type natriuretic peptide as a predictor of mortality in community-dwelling older adults with Chagas disease: 10-year follow-up of the Bambuí Cohort Study of Aging. Am. J. Epidemiol. 172, 190-196 (2010).
110. Moreira, M. C., Wang, Y., Heringer-Walther, S., Wessel, N. & Walther, T. Prognostic value of natriuretic peptides in Chagas' disease: a head-to-head comparison of the 3 natriuretic peptides. Congest. Heart Fail. 15, 75-81 (2009).
111. Saravia, S. G. et al. Cardiac troponin T measured with a highly sensitive assay for diagnosis and monitoring of heart injury in chronic Chagas disease. Arch. Pathol. Lab. Med. 135, 243-248 (2011).
112. Cunha-Neto, E. et al. Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy. Mem. Inst. Oswaldo Cruz 104 (Suppl. 1), 252-258 (2009).
113. Talvani, A. et al. Elevated concentrations of CCL2 and tumor necrosis factor-α in chagasic cardiomyopathy. Clin. Infect. Dis. 38, 943-950 (2004).
114. Nunes, M. C. et al. Risk estimation approach in Chagas disease is still needed. Int. J. Cardiol. 147, 294-296 (2011).
115. Kuschnir, E. et al. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy [Spanish]. Arq. Bras. Cardiol. 45, 249-256 (1985).
116. Andrade, J. P. et al. I. Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy [Portuguese]. Arq. Bras. Cardiol. 97 (Suppl. 3), 1-48 (2011).
117. Gonçalves, J. G., Dias Silva, V. J., Calzada Borges, M. C., Prata, A. & Correia, D. Mortality indicators among chronic Chagas patients living in an endemic area. Int. J. Cardiol. 143, 235-242 (2010).
118. Salles, G., Xavier, S., Sousa, A., Hasslocher-Moreno, A. & Cardoso, C. Prognostic value of QT interval parameters for mortality risk stratification in Chagas' disease: results of a long-term follow-up study. Circulation 108, 305-312 (2003).
119. Salles, G. F., Xavier, S. S., Sousa, A. S., Hasslocher-Moreno, A. & Cardoso, C. R. T-wave axis deviation as an independent predictor of mortality in chronic Chagas' disease. Am. J. Cardiol. 93, 1136-1140 (2004).
120. Ribeiro, A. L. et al. T-wave amplitude variability and the risk of death in chagas disease. J. Cardiovasc. Electrophysiol. 22, 799-805 (2011).
121. Ardito, S. Q., Bestetti, R. B., Cardinalli-Neto, A., Otaviano, A. P. & Nogueira, P. R. Chronic renal impairment in patients with Chagas cardiomyopathy with chronic systolic heart failure: prevalence and prognostic significance. Int. J. Cardiol. 152, 133-134 (2011).
122. Basquiera, A. L. et al. Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction. Heart 89, 1186-1190 (2003).
123. Pedrosa, R. C., Salles, J. H., Magnanini, M. M., Bezerra, D. C. & Bloch, K. V. Prognostic value of exercise-induced ventricular arrhythmia in Chagas' heart disease. Pacing Clin. Electrophysiol. 34, 1492-1497 (2011).
124. Rocha, M. O. & Ribeiro, A. L. A risk score for predicting death in Chagas' heart disease. N. Engl. J. Med. 355, 2488-2489 (2006).
125. Benchimol-Barbosa, P. R. Nonlinear mathematical model for predicting long term cardiac remodeling in Chagas' heart disease: introducing the concepts of 'limiting cardiac function' and 'cardiac function deterioration period'. Int. J. Cardiol. 145, 219-221 (2009).
126. Ribeiro, A. L., Lombardi, F., Colosimo, E. A., Nunes, M. C. & Rocha, M. O. Risk stratification in Chagas disease: further improvements are needed. J. Cardiovasc. Electrophysiol. 19, E41-E43 (2008).
127. Bern, C. Antitrypanosomal therapy for chronic Chagas' disease. N. Engl. J. Med. 364, 2527-2534 (2011).
128. Clayton, J. Chagas disease: pushing through the pipeline. Nature 465, S12-S15 (2010).
129. Coura, J. R. & Borges-Pereira, J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem. Inst. Oswaldo Cruz 106, 641-645 (2011).
130. Rassi, A. Jr, Rassi, A. & Marin-Neto, J. A. Chagas disease. Lancet 375, 1388-1402 (2010).
131. Viotti, R. & Vigliano, C. Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine. Expert Rev. Anti Infect. Ther. 5, 717-726 (2007).
132. Bern, C. et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298, 2171-2181 (2007).
133. Organizacíon Panamericana de la Salud/Organizacíon Mundial de la Salud. Tratamiento Etiológico de la Enfermedad de Chagas. Conclusiones de una Consulta Técnica (OPS/HCP/HCT/140/99) [Spanish; online], http://www.paho.org/Spanish/AD/DPC/CD/chagas.pdf (1998).
134. Garcia, S. et al. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob. Agents Chemother. 49, 1521-1528 (2005).
135. Viotti, R. et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med. 144, 724-734 (2006).
136. Mady, C., Ianni, B. M. & de Souza, J. L. Jr. Benznidazole and Chagas disease: can an old drug be the answer to an old problem? Expert Opin. Investig. Drugs 17, 1427-1433 (2008).
137. Issa, V. S. & Bocchi, E. A. Antitrypanosomal agents: treatment or threat? Lancet 376, 768-769 (2010).
138. Pérez-Molina, J. A. et al. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J. Antimicrob. Chemother. 64, 1139-1147 (2009).
139. Marin-Neto, J. A. et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem. Inst. Oswaldo Cruz 104 (Suppl. 1), 319-324 (2009).
140. Sosa-Estani, S., Cura, E., Velazquez, E., Yampotis, C. & Segura, E. L. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev. Soc. Bras. Med. Trop. 42, 484-487 (2009).
141. Viotti, R. et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti Infect. Ther. 7, 157-163 (2009).
142. Castro, J. A., de Mecca, M. M. & Bartel, L. C. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum. Exp. Toxicol. 25, 471-479 (2006).
143. Olivieri, B. P. et al. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int. J. Antimicrob. Agents 36, 79-83 (2010).
144. Diniz, L. F. et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob. Agents Chemother. 54, 2979-2986 (2010).
145. Urbina, J. A. et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 21, 39-48 (2003).
146. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01377480 (2012).
147. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01489228 (2011).
148. Benaim, G. et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J. Med. Chem. 49, 892-899 (2006).
149. Benaim, G. et al. In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile. Antimicrob. Agents Chemother. 56, 3720-3725 (2012).
150. McKerrow, J. H. et al. Two approaches to discovering and developing new drugs for Chagas disease. Mem. Inst. Oswaldo Cruz 104 (Suppl. 1), 263-269 (2009).
151. Viotti, R. et al. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl. Trop. Dis. 5, e1314 (2011).
152. Murcia, L., Carrilero, B., Munoz, M. J., Iborra, M. A. & Segovia, M. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country. J. Antimicrob. Chemother. 65, 1759-1764 (2010).
153. Schijman, A. G. et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl. Trop. Dis. 5, e931 (2011).
154. Gomes, M. L., Galvao, L. M., Macedo, A. M., Pena, S. D. & Chiari, E. Chagas' disease diagnosis: comparative analysis of parasitologic, molecular, and serologic methods. Am. J. Trop. Med. Hyg. 60, 205-210 (1999).
155. Muratore, C. A. & Baranchuk, A. Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy. Vasc. Health Risk Manag. 6, 593-601 (2010).
156. Botoni, F. A. et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am. Heart J. 153, 544.e1-8 (2007).
157. Bestetti, R. B. et al. Effects of β-blockers on outcome of patients with Chagas' cardiomyopathy with chronic heart failure. Int. J. Cardiol. 151, 205-208 (2011).
158. Issa, V. S. et al. β-Blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ. Heart Fail. 3, 82-88 (2010).
159. Quiros, F. R., Morillo, C. A., Casas, J. P., Cubillos, L. A. & Silva, F. A. CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]. Trials 7, 21 (2006).
160. Bocchi, E. A. & Fiorelli, A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First guidelines group for heart transplantation of the Brazilian Society of Cardiology. Ann. Thorac. Surg. 71, 1833-1838 (2001).
161. Fiorelli, A. I. et al. Heart transplantation in 107 cases of Chagas' disease. Transplant. Proc. 43, 220-224 (2011).
162. de Carvalho, A. C., Carvalho, A. B. & Goldenberg, R. C. Cell-based therapy in Chagas disease. Adv. Parasitol. 75, 49-63 (2011).
163. Ribeiro dos Santos, R. et al. Cell therapy in Chagas cardiomyopathy (Chagas arm of the MiHeart Study): a multicenter randomized trial. Circulation 125, 2454-2461 (2012).
164. Lima, M. M. et al. A randomized trial of the effects of exercise training in Chagas cardiomyopathy. Eur. J. Heart Fail. 12, 866-873 (2010).
165. Mendoza, I. et al. Consensus of the electrophysiology committee of "USCAS" on the treatment of ventricular arrhythmias in Chagas disease [Portuguese]. Arq. Bras. Cardiol. 62, 41-43 (1994).
166. Rassi, A. Jr, Rassi, A. G., Rassi, S. G., Rassi, L. Jr & Rassi, A. Ventricular arrhythmia in Chagas disease. Diagnostic, prognostic, and therapeutic features [Portuguese]. Arq. Bras. Cardiol. 65, 377-387 (1995).
167. Rosa, R. F., Neto, A. S. & Franken, R. A. Chagas' disease and the use of implantable cardioverter-defibrillators in Brazil. Am. J. Geriatr. Cardiol. 15, 372-376 (2006).
168. Cardinalli-Neto, A., Greco, O. T. & Bestetti, R. B. Automatic implantable cardioverter-defibrillators in Chagas' heart disease patients with malignant ventricular arrhythmias. Pacing Clin. Electrophysiol. 29, 467-470 (2006).
169. Muratore, C. A. et al. Implantable cardioverter defibrillators and Chagas' disease: results of the ICD Registry Latin America. Europace 11, 164-168 (2009).
170. Bestetti, R. & Cardinalli-Neto, A. Implantable cardioverter defibrillator therapy for patients with chronic Chagas' disease: a randomized trial may not be necessary in high-risk patients. Europace 11, 537 (2009).
171. Leite, L. R., Fenelon, G., Paes, A. T. & de Paola, A. A. The impact of syncope during clinical presentation of sustained ventricular tachycardia on total and cardiac mortality in patients with chronic Chagasic heart disease. Arq. Bras. Cardiol. 77, 439-452 (2001).
172. Epstein, A. E. et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 5, e1-e62 (2008).
173. Rassi, A. Jr, Rassi, S. G. & Rassi, A. Sudden death in Chagas' disease. Arq. Bras. Cardiol. 76, 75-96 (2001).
174. de Paola, A. A., Gondin, A. A., Hara, V. & Mendonça, A. Medical treatment of cardiac arrhythmias in Chagas' heart disease. Sao Paulo Med. J. 113, 858-861 (1995).
175. Cardinalli-Neto, A., Bestetti, R. B., Cordeiro, J. A. & Rodrigues, V. C. Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy. J. Cardiovasc. Electrophysiol. 18, 1236-1240 (2007).
176. d'Avila, A. et al. New perspectives on catheter-based ablation of ventricular tachycardia complicating Chagas' disease: experimental evidence of the efficacy of near infrared lasers for catheter ablation of Chagas' VT. J. Interv. Card. Electrophysiol. 7, 23-38 (2002).
177. Sweeney, M. O. & Hellkamp, A. S. Heart failure during cardiac pacing. Circulation 113, 2082-2088 (2006).
178. Chagas, C. R. J. Nova tripanozomiase humana: estudos sobre a morfologia e o ciclo evolutivo do Schizotrypanum cruzi, n. gen., n. sp, ajente etiolojico de nova entidade morbida do homem [Portuguese]. Mem. Inst. Oswaldo Cruz 1, 159-219 (1909).
179. Sarabanda, A. V. & Marin-Neto, J. A. Predictors of mortality in patients with Chagas' cardiomyopathy and ventricular tachycardia not treated with implantable cardioverter-defibrillators. Pacing Clin. Electrophysiol. 34, 54-62 (2011).
180. Theodoropoulos, T. A. et al. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy. Int. J. Cardiol. 128, 22-29 (2008).